Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

Docetaxel 17Surveys and Questionnaires 15pembrolizumab 14Specimen Handling 10Radiotherapy 10Early Intervention, Educational 10Zoledronic Acid 9Interviews as Topic 9olaparib 8Standard of Care 8Psychiatric Rehabilitation 8Therapeutics 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Fulvestrant 7durvalumab 6Paclitaxel 6Nivolumab 6Methods 6Educational Status 6Carboplatin 6enzalutamide 5Trastuzumab 5Radiosurgery 5Exercise 5Cyclophosphamide 5palbociclib 4Taxes 4Sirolimus 4Letrozole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × AZD5305 × Breast × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡